Please enable Javascript
Upper Tract Urothelial Carcinoma
Advertisement
Nomogram Predicts Probability of Extraurothelial Recurrence in UTUC After RNU
Emily Menendez
Upper Tract Urothelial Carcinoma
|
September 22, 2023
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
Read More
Patients Over 70 Who Undergo Radical Nephroureterectomy for UTUC May Have Worse Outcomes
Emily Menendez
Upper Tract Urothelial Carcinoma
|
September 8, 2023
Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes.
Read More
Platinum, Gemcitabine Combination Improves OS, CSS in UTUC
Emily Menendez
Upper Tract Urothelial Carcinoma
|
August 17, 2023
Patients who had initiated AC 90 days after RNU were examined to determine a relation between treatment efficacy and timing.
Read More
Expert Insights on Lymph Node Dissection, Kidney-Sparing Management
David Ambinder, MD
Upper Tract Urothelial Carcinoma
|
July 31, 2023
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
Read More
Impact of the OLYMPUS Trial on Nephron-Sparing Management for Upper Tract Disease
David Ambinder, MD
Upper Tract Urothelial Carcinoma
|
July 31, 2023
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
Read More
ROBUUST Database Shows Impact of Variant Histology on UTUC Outcomes
Emily Menendez
Upper Tract Urothelial Carcinoma
|
July 13, 2023
The implications of VH have been thoroughly studied in bladder cancer, but further investigation is needed in UTUC.
Read More
The OLYMPUS Trial for Patients With Low-Grade UTUC
Surena F. Matin, MD
Upper Tract Urothelial Carcinoma
|
July 7, 2023
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
View More
Kidney Sparing in UTUC: The Right Patients and Optimal Techniques
Surena F. Matin, MD
Upper Tract Urothelial Carcinoma
|
July 7, 2023
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
View More
Lymphadenectomy for UTUC: Staging and Therapeutic Considerations
Surena F. Matin, MD
Upper Tract Urothelial Carcinoma
|
July 7, 2023
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
View More
Mitomycin Gel AEs and Administration in the Community Setting
Katie S. Murray, DO
Upper Tract Urothelial Carcinoma
|
July 5, 2023
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
View More
Effective Techniques for Nephron Sparing, Mitomycin Gel for UTUC
Katie S. Murray, DO
Upper Tract Urothelial Carcinoma
|
July 5, 2023
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
View More
ICIs, ADCs, and VEGF Inhibitors in Upper Tract Urothelial Disease
Petros Grivas, MD, PhD
Upper Tract Urothelial Carcinoma
|
June 29, 2023
ICIs for upper tract disease after upfront chemotherapy, along with the emerging role of targeted therapies.
View More
Neoadjuvant, Adjuvant Therapy in Upper, Lower Tract Urothelial Disease With Drs. Grivas, Wallis
Petros Grivas, MD, PhD
Upper Tract Urothelial Carcinoma
|
June 29, 2023
Approaching perioperative systemic therapy in upper and lower tract disease, including neoadjuvant and adjuvant therapy.
View More
Updated AUA/SUO Guideline on UTUC Includes Recommendations for Chemotherapy, Immunotherapy
David Ambinder, MD
Upper Tract Urothelial Carcinoma
|
June 28, 2023
The recently released AUA/SUO guideline on UTUC includes 6 guidelines on neoadjuvant/adjuvant chemotherapy and immunotherapy.
Read More
The Landscape of UTUC Treatment Integration: Drs. Coleman and Wallis
Jonathan Coleman, MD
Upper Tract Urothelial Carcinoma
|
June 14, 2023
Assessing the treatment landscape in UTUC and how many different patient biomarkers influence treatment integration.
View More
Vascular-Targeted Photodynamic Therapy for UTUC With Drs. Coleman and Wallis
Jonathan Coleman, MD
Upper Tract Urothelial Carcinoma
|
June 14, 2023
A continuation of the discussion on UTUC vascular-targeted photodynamic therapy as a way of nephron-sparing for patients.
View More
UTUC Risk Stratification and Alternative Biomarkers
Jonathan Coleman, MD
Upper Tract Urothelial Carcinoma
|
June 14, 2023
Breaking down the differences in "high risk" and "low risk" stratification in the UTUC guideline, and other biomarkers.
View More
Neoadjuvant Therapy for UTUC and Treatment Guidelines: Drs. Coleman and Wallis
Jonathan Coleman, MD
Upper Tract Urothelial Carcinoma
|
June 14, 2023
A summary of the therapeutic strategies available for avoiding surgery for UTUC, as well as other management considerations.
View More
Infigratinib as Adjuvant Therapy for UC: Results From PROOF 302
Emily Menendez
ASCO 2023
|
June 1, 2023
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
Read More
Kidney-Sparing Management for UTUC: A Review of the 2023 AUA/SUO Guideline
David Ambinder, MD
Upper Tract Urothelial Carcinoma
|
May 31, 2023
There are 7 recommendations specific to the appropriateness of and proper technique for kidney-sparing management.
Read More
Load More
Advertisement
Advertisement
Advertisement